Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Single-cell spatial landscapes of the lung tumour immune microenvironmentNature (London), 2023-02, Vol.614 (7948), p.548-554 [Peer Reviewed Journal]2023. The Author(s). ;Copyright Nature Publishing Group Feb 16, 2023 ;The Author(s) 2023 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-022-05672-3 ;PMID: 36725934Full text available |
|
2 |
Material Type: Article
|
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical OutcomesJournal of clinical oncology, 2019-02, Vol.37 (4), p.278-285 [Peer Reviewed Journal]2018 by American Society of Clinical Oncology 2018 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.18.01585 ;PMID: 30550363Full text available |
|
3 |
Material Type: Article
|
miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cellsPloS one, 2013-03, Vol.8 (3), p.e60317-e60317 [Peer Reviewed Journal]COPYRIGHT 2013 Public Library of Science ;2013 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Chen et al 2013 Chen et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0060317 ;PMID: 23555954Full text available |
|
4 |
Material Type: Article
|
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerNature communications, 2015-03, Vol.6 (1), p.6377-6377, Article 6377 [Peer Reviewed Journal]Copyright Nature Publishing Group Mar 2015 ;Copyright © 2015, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/ncomms7377 ;PMID: 25758528Full text available |
|
5 |
Material Type: Article
|
Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 + T cell exhaustionNature communications, 2020-09, Vol.11 (1), p.4520-4520, Article 4520 [Peer Reviewed Journal]The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2041-1723 ;EISSN: 2041-1723 ;DOI: 10.1038/s41467-020-18298-8 ;PMID: 32908154Full text available |
|
6 |
Material Type: Article
|
Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancerCochrane database of systematic reviews, 2015-03, Vol.2015 (3), p.CD011430-CD011430 [Peer Reviewed Journal]Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;ISSN: 1469-493X ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD011430 ;PMID: 25730344Full text available |
|
7 |
Material Type: Article
|
Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancerPloS one, 2012-04, Vol.7 (4), p.e35065-e35065 [Peer Reviewed Journal]COPYRIGHT 2012 Public Library of Science ;COPYRIGHT 2012 Public Library of Science ;2012 Lv et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Lv et al. 2012 ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0035065 ;PMID: 22493729Full text available |
|
8 |
Material Type: Article
|
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyThe lancet oncology, 2018-01, Vol.19 (1), p.139-148 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2018 Elsevier B.V. ;Copyright Elsevier Limited Jan 1, 2018 ;2018. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30729-5 ;PMID: 29174310Full text available |
|
9 |
Material Type: Article
|
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialThe lancet oncology, 2019-12, Vol.20 (12), p.1655-1669 [Peer Reviewed Journal]2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;2019. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30634-5 ;PMID: 31591063Full text available |
|
10 |
Material Type: Article
|
The evolution of lung cancer and impact of subclonal selection in TRACERxNature (London), 2023-04, Vol.616 (7957), p.525-533 [Peer Reviewed Journal]2023. The Author(s). ;Copyright Nature Publishing Group Apr 20, 2023 ;The Author(s) 2023 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-023-05783-5 ;PMID: 37046096Full text available |
|
11 |
Material Type: Article
|
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerThe New England journal of medicine, 2017-11, Vol.377 (20), p.1919-1929 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1709937 ;PMID: 28885881Full text available |
|
12 |
Material Type: Article
|
Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancerPloS one, 2021-12, Vol.16 (12), p.e0260988-e0260988 [Peer Reviewed Journal]COPYRIGHT 2021 Public Library of Science ;2021 Rice, Belani. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Rice, Belani 2021 Rice, Belani ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0260988 ;PMID: 34855926Full text available |
|
13 |
Material Type: Article
|
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerThe Journal of clinical investigation, 2019-03, Vol.129 (3), p.1211-1228 [Peer Reviewed Journal]COPYRIGHT 2019 American Society for Clinical Investigation ;COPYRIGHT 2019 American Society for Clinical Investigation ;Copyright American Society for Clinical Investigation Mar 2019 ;Copyright © 2019, American Society for Clinical Investigation 2019 American Society for Clinical Investigation ;ISSN: 0021-9738 ;EISSN: 1558-8238 ;DOI: 10.1172/jci123319 ;PMID: 30589644Full text available |
|
14 |
Material Type: Article
|
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancerBritish journal of cancer, 2019-09, Vol.121 (6), p.490-496 [Peer Reviewed Journal]Copyright Nature Publishing Group Sep 2019 ;The Author(s), under exclusive licence to Cancer Research UK 2019 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-019-0541-3 ;PMID: 31388183Full text available |
|
15 |
Material Type: Article
|
Metformin use and lung cancer survival: a population-based study in NorwayBritish journal of cancer, 2021-03, Vol.124 (5), p.1018-1025 [Peer Reviewed Journal]The Author(s), under exclusive licence to Cancer Research UK 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s), under exclusive licence to Cancer Research UK 2020 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-020-01186-9 ;PMID: 33262518Full text available |
|
16 |
Material Type: Article
|
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerThe New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1801005 ;PMID: 29658856Full text available |
|
17 |
Material Type: Article
|
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of oncology, 2018-10, Vol.29 (Supplement_4), p.iv192-iv237 [Peer Reviewed Journal]The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdy275 ;PMID: 30285222Full text available |
|
18 |
Material Type: Article
|
Emerging therapeutic agents for advanced non-small cell lung cancerJournal of hematology and oncology, 2020-05, Vol.13 (1), p.58-58, Article 58 [Peer Reviewed Journal]COPYRIGHT 2020 BioMed Central Ltd. ;COPYRIGHT 2020 BioMed Central Ltd. ;2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 1756-8722 ;EISSN: 1756-8722 ;DOI: 10.1186/s13045-020-00881-7 ;PMID: 32448366Full text available |
|
19 |
Material Type: Article
|
Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung CancerThe New England journal of medicine, 2023-02, Vol.388 (6), p.489-498 [Peer Reviewed Journal]Copyright © 2023 Massachusetts Medical Society. All rights reserved. ;Copyright © 2023 Massachusetts Medical Society. ;COPYRIGHT 2023 Massachusetts Medical Society ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2212083 ;PMID: 36780674Full text available |
|
20 |
Material Type: Article
|
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expressionAnnals of oncology, 2019-10, Vol.30 (10), p.1653-1659 [Peer Reviewed Journal]2019 THE AUTHORS ;The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz288 ;PMID: 31435660Full text available |